CClinicalTrials.gg
Status unknownNCT00470769Updated May 8, 2007

The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR

An observational study in Hypertension and Renal Failure, sponsored by University of Roma La Sapienza. Status unknown at 3 sites in Italy. Open to participants aged 30 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-05-08.

Sponsored by University of Roma La Sapienza · Observational

The sponsor has not verified this record recently (last verified May 2007), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Defined population
Time perspective
Other
Enrollment
2,006
Ages
30 Years to 80 Years
Sex
All
01

Study summary

It is generally assumed that renal blood flow is symmetric in the absence of renal artery stenosis. The importance of studying the function of both kidneys separately is because it cannot be assumed that they are functionally equal.The aim of the present study is to evaluate whether this is really in patients with essential hypertension and/or moderate kidneys loss.

Read the detailed description

To validate color Doppler ultrasonography of renal arteries for the assessment of renal blood flow (RBF), we comparing left and right RBF estimates and their sum (total RBF) by echo-Doppler with data obtained by 99mTc-DTPA scintigraphy in 50 patients with hypertension and/or moderate renal failure, compared with 30 normal control subjects.

02

Conditions studied

  • Hypertension
  • Renal Failure

Browse trials for

Keywords

  • Color-Doppler Ultrasonography
  • Renal scintigraphy
  • Kidney failure
  • GFR
03

In context

Renal Insufficiency

1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.

This study's planned enrollment of 2,006 is above the median of 149 across 394 observational studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

University of Roma La Sapienza is the lead sponsor of 388 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients with hypertension
  • Patients with moderate renal insufficiency
  • Normal subjects

Exclusion criteria

Exclusion Criteria:

  • Patients with solitary kidney function
  • Patients with renal artery stenosis
  • Patients underwent renal angioplasty and stenting
05

Study design

Observational model
Defined population
Time perspective
Other
Enrollment
2,006 participants (estimated)

Interventions

  • ProcedureColor-Doppler Ultrasound, 99mTc-DTPA scintigraphy
06

Study locations

3 of 3 sites recruiting
  • Giorgio Fuiano
    Catanzaro, 88020, Italy
    Recruiting
  • University of Rome La Sapienza
    Roma, 00100, Italy
    Recruiting
  • Rosario Cianci
    Rome, 00100, Italy
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00470769
Lead sponsor
University of Roma La Sapienza
First posted
May 8, 2007
Start date
Sep 2006
Completion
May 2007 (estimated)
Last update
May 8, 2007

Study contacts

Rosario Cianci, MD
Contact
ciancirosario@tin.it
+39335206441
Rosario Cianci, MD
principal investigator · Department Of Clinic Medicine, Chair of Nephrology
Giorgio Fuiano, MD
study director · University of Catanzaro

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion